Discussion	O

In	O
our	O
previous	O
work	O
,	O
we	O
considered	O
in	O
CD	O
families	O
the	O
risk	O
to	O
develop	O
the	O
disease	O
according	O
to	O
a	O
specific	O
HLA	O
haplotypes	O
,	O
obtaining	O
a	O
risk	O
range	O
from	O
0	O
.	O
01	O
to	O
>	O
=	O
0	O
.	O
20	O
[	O
1	O
]	O
.	O

In	O
the	O
present	O
study	O
we	O
evaluated	O
the	O
role	O
of	O
3	O
non	O
-	O
HLA	O
genetic	O
markers	O
to	O
influence	O
the	O
CD	O
risk	O
in	O
first	O
relatives	O
of	O
CD	O
affected	O
children	O
.	O

We	O
collected	O
data	O
on	O
families	O
with	O
at	O
least	O
one	O
CD	O
-	O
affected	O
among	O
offspring	O
.	O

This	O
family	O
set	O
helped	O
to	O
evaluate	O
the	O
association	O
between	O
SNPs	O
and	O
CD	O
(	O
TDT	O
on	O
parents	O
-	O
offspring	O
trios	O
)	O
and	O
to	O
estimate	O
the	O
risk	O
of	O
CD	O
in	O
the	O
other	O
sibs	O
.	O

The	O
TDT	O
design	O
provides	O
robustness	O
to	O
population	O
stratification	O
and	O
mitigation	O
of	O
the	O
possible	O
confounding	O
effect	O
of	O
environmental	O
factors	O
,	O
because	O
all	O
family	O
members	O
share	O
the	O
same	O
environment	O
[	O
16	O
]	O
.	O

Ten	O
SNPs	O
,	O
selected	O
from	O
those	O
previously	O
found	O
to	O
be	O
associated	O
with	O
CD	O
by	O
GWAS	O
[	O
13	O
]	O
,	O
were	O
successfully	O
genotyped	O
.	O

In	O
our	O
population	O
three	O
SNPs	O
resulted	O
significantly	O
associated	O
with	O
CD	O
(	O
those	O
in	O
LPP	O
,	O
RGS1	O
and	O
REL	O
genes	O
)	O
and	O
the	O
other	O
seven	O
investigated	O
SNPs	O
,	O
even	O
if	O
not	O
statistically	O
associated	O
with	O
CD	O
,	O
showed	O
always	O
an	O
higher	O
frequency	O
of	O
the	O
previously	O
reported	O
risk	O
alleles	O
[	O
13	O
]	O
in	O
affected	O
subjects	O
than	O
in	O
controls	O
.	O

The	O
three	O
genes	O
selected	O
appear	O
to	O
be	O
appealing	O
for	O
the	O
pathogenesis	O
of	O
CD	O
.	O

LPP	O
(	O
OR	O
=	O
2	O
.	O
36	O
;	O
p	O
<	O
0	O
.	O
001	O
)	O
was	O
reported	O
to	O
be	O
highly	O
expressed	O
in	O
small	B-Multi-tissue_structure
intestinal	I-Multi-tissue_structure
mucosa	I-Multi-tissue_structure
and	O
may	O
have	O
a	O
structural	O
role	O
at	O
sites	B-Cellular_component
of	O
cell	B-Cell
adhesion	O
in	O
maintaining	O
cell	B-Cell
shape	O
and	O
motility	O
[	O
7	O
]	O
.	O

RGS1	O
(	O
OR	O
=	O
1	O
.	O
75	O
;	O
p	O
=	O
0	O
.	O
025	O
)	O
belongs	O
to	O
a	O
family	O
of	O
RGS	O
genes	O
.	O

It	O
attenuates	O
the	O
signaling	O
activity	O
of	O
G	O
-	O
proteins	O
,	O
blocking	O
the	O
homing	O
of	O
Intra	B-Cell
Epithelial	I-Cell
Lymphocytes	I-Cell
(	O
IELs	B-Cell
)	O
,	O
and	O
it	O
is	O
specifically	O
expressed	O
both	O
in	O
human	O
small	B-Multi-tissue_structure
intestinal	I-Multi-tissue_structure
mucosa	I-Multi-tissue_structure
and	O
in	O
murine	O
IELs	B-Cell
,	O
key	O
players	O
in	O
the	O
development	O
of	O
human	O
CD	O
villous	O
atrophy	O
[	O
7	O
]	O
,	O
[	O
17	O
]	O
.	O

REL	O
(	O
OR	O
=	O
1	O
.	O
66	O
;	O
p	O
=	O
0	O
.	O
034	O
)	O
is	O
a	O
subunit	O
of	O
NF	O
-	O
kB	O
complex	O
,	O
implicated	O
in	O
T	B-Cell
cell	I-Cell
differentiation	O
[	O
18	O
]	O
and	O
it	O
appears	O
to	O
be	O
a	O
key	O
molecule	O
regulating	O
inflammation	O
and	O
the	O
switch	O
from	O
tolerance	O
to	O
autoimmunity	O
[	O
19	O
]	O
.	O

It	O
is	O
interesting	O
to	O
note	O
that	O
our	O
data	O
confirm	O
previous	O
pathogenetic	O
implications	O
reported	O
in	O
literature	O
of	O
these	O
SNPs	O
with	O
CD	O
as	O
well	O
as	O
with	O
other	O
autoimmune	O
diseases	O
[	O
20	O
]	O
.	O

By	O
the	O
Bayesian	O
approach	O
we	O
calculated	O
a	O
ranking	O
score	O
(	O
BS	O
)	O
among	O
the	O
sibs	O
.	O

However	O
,	O
it	O
should	O
be	O
considered	O
that	O
BS	O
is	O
not	O
a	O
plain	O
disease	O
risk	O
,	O
rather	O
a	O
method	O
to	O
rank	O
different	O
genotypes	O
according	O
to	O
their	O
contribution	O
to	O
make	O
an	O
individual	O
susceptible	O
to	O
CD	O
.	O

For	O
instance	O
,	O
some	O
of	O
our	O
BS	O
are	O
very	O
near	O
to	O
1	O
,	O
nevertheless	O
none	O
of	O
the	O
considered	O
genotypes	O
could	O
give	O
a	O
100	O
%	O
risk	O
to	O
develop	O
the	O
disease	O
.	O

In	O
other	O
terms	O
,	O
we	O
considered	O
the	O
BS	O
as	O
a	O
ranking	O
measure	O
,	O
only	O
stating	O
that	O
a	O
given	O
genotype	O
could	O
assign	O
a	O
higher	O
risk	O
than	O
another	O
genotype	O
but	O
does	O
not	O
allow	O
a	O
quantitative	O
measure	O
of	O
the	O
risk	O
difference	O
(	O
2	O
-	O
fold	O
,	O
3	O
-	O
fold	O
,	O
etc	O
)	O
.	O

However	O
,	O
even	O
if	O
the	O
addition	O
of	O
only	O
3	O
SNPs	O
to	O
HLA	O
could	O
be	O
considered	O
at	O
"	O
minor	O
effect	O
"	O
[	O
13	O
]	O
,	O
we	O
demonstrated	O
that	O
they	O
could	O
significantly	O
improve	O
the	O
prediction	O
of	O
CD	O
risk	O
in	O
sibs	O
,	O
in	O
terms	O
of	O
diagnostic	O
sensitivity	O
and	O
negative	O
predictive	O
value	O
.	O

So	O
,	O
in	O
a	O
cohort	O
of	O
CD	O
families	O
,	O
our	O
data	O
confirm	O
that	O
non	O
-	O
HLA	O
SNPs	O
evaluation	O
is	O
an	O
usefull	O
diagnostic	O
tool	O
in	O
CD	O
risk	O
evaluation	O
as	O
a	O
previous	O
study	O
showed	O
in	O
CD	O
unrelated	O
subjects	O
[	O
14	O
]	O
.	O

CD	O
,	O
on	O
the	O
basis	O
of	O
the	O
actual	O
knowledge	O
,	O
cannot	O
be	O
exactly	O
predicted	O
by	O
genetic	O
testing	O
,	O
but	O
a	O
reliable	O
probabilistic	O
method	O
might	O
be	O
associated	O
to	O
careful	O
surveillance	O
of	O
infants	O
carrying	O
the	O
higher	O
risk	O
.	O

This	O
will	O
help	O
to	O
significantly	O
reduce	O
the	O
heavy	O
load	O
of	O
anxiety	O
and	O
pain	O
associated	O
with	O
the	O
appearance	O
of	O
symptoms	O
of	O
CD	O
,	O
by	O
anticipating	O
,	O
with	O
simple	O
serological	O
tests	O
,	O
the	O
clinical	O
appearance	O
of	O
the	O
disease	O
.	O

To	O
improve	O
the	O
possibility	O
to	O
identify	O
high	O
risk	O
patients	O
in	O
CD	O
families	O
we	O
propose	O
in	O
alternative	O
to	O
the	O
classical	O
HLA	O
classification	O
(	O
Fig	O
.	O
4	O
,	O
panel	O
A	O
)	O
a	O
slight	O
improved	O
flow	O
-	O
chart	O
(	O
Fig	O
.	O
4	O
,	O
panel	O
B	O
)	O
:	O
1	O
)	O
HLA	O
genotyping	O
:	O
subjects	O
belonging	O
to	O
the	O
HLA	O
risk	O
groups	O
1	O
and	O
2	O
will	O
be	O
classified	O
as	O
at	O
high	O
CD	O
risk	O
;	O
2	O
)	O
subjects	O
belonging	O
to	O
the	O
HLA	O
risk	O
groups	O
3	O
and	O
4	O
,	O
will	O
be	O
further	O
investigated	O
for	O
our	O
SNPs	O
combination	O
(	O
LPP	O
,	O
REL	O
,	O
RGS1	O
)	O
in	O
order	O
to	O
calculate	O
their	O
BS	O
(	O
Fig	O
.	O
4	O
,	O
panel	O
B	O
)	O
.	O

Among	O
these	O
latter	O
subjects	O
those	O
with	O
a	O
BS	O
>	O
=	O
the	O
median	O
value	O
will	O
be	O
classified	O
at	O
high	O
risk	O
;	O
3	O
)	O
subjects	O
belonging	O
to	O
the	O
HLA	O
risk	O
group	O
5	O
will	O
be	O
considered	O
at	O
low	O
CD	O
risk	O
.	O

All	O
CD	O
familials	O
belonging	O
to	O
the	O
above	O
high	O
risk	O
groups	O
(	O
HLA	O
group	O
1	O
-	O
2	O
and	O
HLA	O
group	O
3	O
-	O
4	O
with	O
BS	O
>	O
=	O
median	O
)	O
will	O
be	O
undergo	O
a	O
strict	O
surveillance	O
.	O

10	O
.	O
1371	O
/	O
journal	O
.	O
pone	O
.	O
0026920	O
.	O
g004	O
Figure	O
4	O

Classification	O
flow	O
-	O
chart	O
.	O

In	O
panel	O
A	O
the	O
classical	O
HLA	O
-	O
based	O
classification	O
.	O

In	O
panel	O
B	O
the	O
proposed	O
BS	O
-	O
based	O
classification	O
considering	O
the	O
genotypes	O
of	O
HLA	O
plus	O
LPP	O
,	O
RGS1	O
and	O
REL	O
SNPs	O
.	O

One	O
of	O
the	O
limitation	O
of	O
our	O
cohort	O
family	O
study	O
could	O
be	O
the	O
sample	O
size	O
,	O
which	O
may	O
have	O
not	O
allowed	O
to	O
explore	O
genes	O
at	O
smaller	O
effect	O
,	O
so	O
explaining	O
the	O
lack	O
of	O
association	O
between	O
SNPs	O
in	O
TAGAP	O
,	O
IL2	O
/	O
IL21	O
,	O
OLIG3	O
,	O
CCR	O
,	O
SH2B3	O
,	O
IL12A	O
and	O
IL12A	O
/	O
SCHIP1	O
genes	O
with	O
CD	O
although	O
the	O
trend	O
observed	O
in	O
previous	O
studies	O
in	O
unrelated	O
CD	O
patients	O
was	O
confirmed	O
[	O
13	O
]	O
.	O

In	O
the	O
main	O
time	O
the	O
homogeneity	O
of	O
the	O
genetic	O
and	O
environmental	O
domains	O
in	O
the	O
tested	O
families	O
allows	O
to	O
explore	O
risk	O
factors	O
within	O
a	O
controlled	O
cohort	O
.	O

A	O
second	O
limit	O
of	O
the	O
study	O
is	O
the	O
relatively	O
short	O
(	O
6	O
years	O
)	O
follow	O
up	O
of	O
the	O
sibship	O
,	O
which	O
could	O
cause	O
an	O
underestimation	O
of	O
the	O
disease	O
development	O
at	O
later	O
ages	O
.	O

Our	O
aim	O
is	O
to	O
go	O
on	O
with	O
the	O
monitoring	O
of	O
these	O
families	O
in	O
the	O
next	O
years	O
.	O

In	O
conclusion	O
,	O
the	O
estimate	O
of	O
the	O
CD	O
risk	O
by	O
HLA	O
+	O
SNPs	O
approach	O
,	O
even	O
if	O
not	O
applicable	O
to	O
prevention	O
,	O
could	O
be	O
a	O
precious	O
tool	O
improving	O
CD	O
diagnosis	O
respect	O
to	O
the	O
only	O
HLA	O
(	O
NPV	O
:	O
95	O
%	O
vs	O
91	O
%	O
,	O
and	O
DS	O
:	O
79	O
%	O
vs	O
45	O
%	O
)	O
,	O
in	O
the	O
cohort	O
of	O
first	O
degree	O
relatives	O
.	O

In	O
fact	O
in	O
clinical	O
practice	O
the	O
absence	O
of	O
HLA	O
risk	O
groups	O
1	O
or	O
2	O
,	O
allows	O
to	O
exclude	O
the	O
disease	O
with	O
high	O
probability	O
,	O
while	O
testing	O
the	O
three	O
SNPs	O
in	O
HLA	O
groups	O
3	O
or	O
4	O
could	O
represent	O
a	O
further	O
tool	O
to	O
identify	O
less	O
frequent	O
CD	O
cases	O
.	O

So	O
,	O
an	O
infant	O
with	O
high	O
HLA	O
+	O
SNPs	O
score	O
even	O
if	O
belonging	O
to	O
HLA	O
low	O
risk	O
groups	O
,	O
shall	O
undergo	O
a	O
simple	O
surveillance	O
system	O
to	O
allow	O
proper	O
diagnosis	O
and	O
treatment	O
before	O
the	O
full	O
blow	O
disease	O
appears	O
.	O

